1Ohtake N, Okarnoto O, Mitomo R, et al. 1β-methyl-2-( 5-sustituted pyrrolidin-3-ylthio) carbapenerns: 3. Synthesis and antibacterial activity of 130-2727 and its related compounds[J]. J Antilriotics, 1997,50 ( 2 ) : 598 - 613.
2Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapanem MK-0826 ( L-749345 ) against broadspectrum and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates[J] .Antimicrob Agems Chemother, 1999,43(5) : 1170 - 1176.
3Gill CL,Jackson JJ, Gerckens LS, et al. In vitro activity and pharmacokinetic evaluation of a new long-acting carbapenem antibiotic, MK-0826 ( L-749345 ) [ J ]. Antimicrob Agents Chemother, 1998,42(8) : 1996 - 2001.
4Sundelof JG, Hajdu R, Gill CJ, et al. Pharmacokineties of L-749345 ,a long-acting carbapenem antibiotic, in primates [J ]. Antimicrob Agents Chemother ,1997.41(8):1743 - 1748.
5Iso Y, Irie T, Iwaki,T, et al. Synthesis and modification of a novel 1β-methyl carbapenem antibiotic, S-4661 [J ]. J Antibiotics ,1996,49(5) :478 - 484.
6Iso Y, Irie T, Nishino Y, et al. A new 1β-methylcarbapenem antibiotic, S-4661: synthesis and structure-activity relationships of 2-(5-substitited pyrrolidin-3-ylthio).1β-methylcarbapenems[J]. J Antibiotics, 1996,49 (2) : 199 - 209.
7Tsuji M, Ishii Y,ohno A,et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem[J]. Antimicrob Agents Chemother, 1998,42 ( 1 ) : 94 - 99.
8Ohba F, Nakamura-Kamijo M,Wastanabe N, et al. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem[ J ]. Antimicrob Agents Chemother, 1997,41(2) :298 - 307.
9Kohler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against Pseudomonas aeruginosa : respective contributions of OprD and efflux systems [ J ]. Antimicrob Agents Chemother, 1999,43(2) : 424 - 427.
10Miyauchi M,Endo R, Hisaoka M, et al. Synthesis and structureactivity relantionshlps of noval oral earbapenem, CS-834 [ J ]. J Antibiotics, 1997,50 (5) : 429 - 439.
1Loan HT,Parry J, Nga NT, et al. Semi -recumbent body position fails to prevent heahhcare-associated pneumonia in Vietnamese patients with severe tetanus[J]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012,106(2) : 90-97.
2Kim JW,Chung J,Choi SH,et al. Early use of imipenem/ cilastatin and vancomycin followed by de-escalation ver- sus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU :A randomized clinical trial[J]. Crit Care,2012,16( 1 ) : R28.
3Chaulagain BP,Jang SJ,Ahn GY,et al. Molecular epi- demiology of an out-break of imipenem-resistant acineto- bacter baumannii carrying the ISAbal-bla(OXA-51-1ike) genes in a Korean hospital[J]. Jpn J Infect Dis,2012,65 (2) : 162-166.
4Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadax-in) enhances the immunogenicity of an adjuvated pandemic H1N1 influenza vaccine (Focetria) in hemodia- lyzed patients:A pilot study[J]. Vaccine,2012,30~6) : 1170- 1180.
5Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumo- nia[J]. Expert Review of Respiratory Medicine,2014,8 (5) :587-596.
6Wang X,Li W,Niu C,et al. Thymosin alpha 1 is associ- ated with improved cellular immunity and reduced infec- tion rate in severe acute pancreatitis patients in a dou- ble-blind randomized control study[J]. Intlammation,2011, 34(3) : 198-202.
7Yang X,Qian F,He HY,et al. Effect of thymosin alpha- 1 on subpopulations of Thl,Th2,Thl7,and regulatory T cells (Tregs) in vitro[J]. Brazilian Journal of Medical and Biological Research, 2012,45 (1) : 25-32.
